B
PTGX icon

Braidwell’s Protagonist Therapeutics PTGX Stock Holding History

Braidwell’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,109
Closed -$776K – 76
2024
Q4 		$776K Buy
+20,109
New +$877K 0.02% 72
2023
Q4 		– Sell
-1,109,150
Closed -$18.5M – 86
2023
Q3 		$18.5M Buy
+1,109,150
New +$21.5M 0.58% 58
2023
Q1 		– Sell
-927,800
Closed -$10.1M – 93
2022
Q4 		$10.1M Buy
+927,800
New +$7.83M 0.34% 71

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Braidwell's PTGX Position: Q1 2025 in Review

Braidwell sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 20,109 shares — an estimated $776K sold.

Braidwell first reported a position in PTGX in Q4 2022 and held it in 3 quarters. The position peaked at $18.5M in Q3 2023. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Braidwell reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Braidwell sold 20,109 Protagonist Therapeutics shares in Q1 2025, an estimated $776K.
  • Braidwell first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 3 quarters.
  • Braidwell's Protagonist Therapeutics position peaked at $18.5M in Q3 2023.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.